Dyspnea, Post-Acute COVID-19, Post COVID-19 Condition, Post Viral Fatigue
Conditions
Keywords
Ventilation Perfusion Mismatch
Brief summary
Prospective cohort study to evaluate the utility of quantitative CT analysis to assess ventilation and perfusion defects in patients with Post-acute Sequelae of SARS-CoV-2 (PASC) and functional limitations
Detailed description
This is a study to describe the overall pattern of lung ventilation and perfusion defects in individuals with PASC. Subjects with PASC with a documented history of COVID-19 and persistent symptoms of fatigue, dyspnea, and/or exercise intolerance will complete questionnaires, and undergo pulmonary function tests, 6-minute walk tests, and a low dose CT chest to describe the overall pattern of lung regional ventilation and blood distribution and to compare this pattern to asymptomatic controls with and without prior COVID-19.
Interventions
DIAGNOSTIC_TESTComputed Tomography of the Chest
Quantitative Computed Tomography of the chest in the inspiratory and expiratory phases will be performed to assess regional lung ventilation as well as pulmonary vascular volume and distribution
Sponsors
4DMedical
Tufts Medical Center
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
Yes
Inclusion criteria
* Age ≥ 18 * Self-reported or documented SARS-CoV-2 infection by RT-PCR or Antigen testing \> 3 months ago or no previous history of SARS-CoV-2 infection (control group only) * Normal or mild abnormalities on baseline Pulmonary Function Tests (PFTs) * New or worsening symptoms of chronic fatigue, dyspnea or exercise intolerance after COVID-19 with otherwise unclear etiology (PASC group only)
Exclusion criteria
* SARS-CoV-2 infection by RT-PCR or Antigen testing within the last 3 months * Inability to provide consent or non-English speaking * Pregnancy * Any respiratory infection in last 4 weeks * PFT relative contraindications * History of major cardiovascular, pulmonary, renal, hepatic, autoimmune or neuromuscular disease including asthma, COPD, interstitial lung disease, heart failure, pulmonary arterial hypertension, or prior pulmonary embolism * Active malignancy undergoing treatment or history of malignancy involving the lung
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measures of regional lung ventilation | 1 day |
| Measures of blood volume distribution | 1 day |
Secondary
| Measure | Time frame |
|---|---|
| Dyspnea severity scores | 1 day |
| Fatigue severity scores | 1 day |
| Quality of life scores | 1 day |
| Six-minute walk distance | 1 day |
Countries
United States
Contacts
Primary ContactBipin Malla
Outcome results
None listed